Quest Diagnostics Incorporated (DGX) is currently priced at $196.35, showing a decrease of -27.5 cents (-0.14%) from the previous close of $196.63. Today's trading volume stands at $174,237, representing a 17.32% deviation from the average.
DGX released its latest earnings on Monday, April 20th, with a consensus EPS estimate of 2.34.
The company offers a forward dividend yield of 1.75% and a dividend per share of 86 cents (MRQ), with a year-over-year increase of 6.6667 cents.
Jefferies maintained a "Buy" rating for DGX on April 21st, with the price at $206.79, suggesting a hold action.
DGX reported a free cash flow of $164 million and ended the period with $393 million in cash.
With revenues at $2.90 billion and net income of $252 million, DGX achieved an EPS of $2.27. The company demonstrated a net profit margin of 8.7%.
Key ratios include a gross profit margin of 32.54%, return on equity of 3.42%, and a price-to-earnings ratio of 21.39.
The balance sheet reveals total assets of $16.67 billion, with total debt at $6.98 billion, leaving a net debt of $6.59 billion.
This comprehensive analysis provides insight into DGX's financial performance, from earnings to cash flow and key ratios, offering investors a snapshot of the company's current standing.
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.